vs
Side-by-side financial comparison of Broadway Financial Corp (BYFC) and Cellectis S.A. (CLLS). Click either name above to swap in a different company.
Cellectis S.A. is the larger business by last-quarter revenue ($9.5M vs $9.4M, roughly 1.0× Broadway Financial Corp). Broadway Financial Corp runs the higher net margin — 1934.0% vs -265.9%, a 2199.9% gap on every dollar of revenue. On growth, Cellectis S.A. posted the faster year-over-year revenue change (375.0% vs 10.1%). Cellectis S.A. produced more free cash flow last quarter ($27.6M vs $-13.0K).
Virtu Financial, Inc. is an American high-frequency trading company. The company went public on the Nasdaq in 2015.
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.
BYFC vs CLLS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2024
| Metric | | |
|---|---|---|
| Revenue | $9.4M | $9.5M |
| Net Profit | $1.0M | $-25.3M |
| Gross Margin | — | — |
| Operating Margin | — | -181.1% |
| Net Margin | 1934.0% | -265.9% |
| Revenue YoY | 10.1% | 375.0% |
| Net Profit YoY | -21.8% | -51.9% |
| EPS (diluted) | $0.02 | $-0.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.4M | — | ||
| Q3 25 | $9.0M | — | ||
| Q2 25 | $8.1M | — | ||
| Q1 25 | $8.3M | — | ||
| Q4 24 | $8.6M | — | ||
| Q3 24 | $8.7M | — | ||
| Q2 24 | $8.2M | $9.5M | ||
| Q1 24 | $7.8M | — |
| Q4 25 | $1.0M | — | ||
| Q3 25 | $-23.9M | — | ||
| Q2 25 | $752.0K | — | ||
| Q1 25 | $-2.7M | — | ||
| Q4 24 | $1.3M | — | ||
| Q3 24 | $516.0K | — | ||
| Q2 24 | $256.0K | $-25.3M | ||
| Q1 24 | $-154.0K | — |
| Q4 25 | — | — | ||
| Q3 25 | -256.2% | — | ||
| Q2 25 | 12.8% | — | ||
| Q1 25 | -45.3% | — | ||
| Q4 24 | 21.7% | — | ||
| Q3 24 | 8.5% | — | ||
| Q2 24 | 4.8% | -181.1% | ||
| Q1 24 | -2.9% | — |
| Q4 25 | 1934.0% | — | ||
| Q3 25 | -264.2% | — | ||
| Q2 25 | 9.3% | — | ||
| Q1 25 | -32.3% | — | ||
| Q4 24 | 15.3% | — | ||
| Q3 24 | 5.9% | — | ||
| Q2 24 | 3.1% | -265.9% | ||
| Q1 24 | -2.0% | — |
| Q4 25 | $0.02 | — | ||
| Q3 25 | $-2.86 | — | ||
| Q2 25 | $0.00 | — | ||
| Q1 25 | $-0.39 | — | ||
| Q4 24 | $0.07 | — | ||
| Q3 24 | $-0.03 | — | ||
| Q2 24 | $0.02 | $-0.28 | ||
| Q1 24 | $-0.02 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.5M | $149.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $262.8M | $148.6M |
| Total Assets | $1.3B | $407.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.5M | — | ||
| Q3 25 | $19.7M | — | ||
| Q2 25 | $29.5M | — | ||
| Q1 25 | $15.8M | — | ||
| Q4 24 | $61.4M | — | ||
| Q3 24 | $97.1M | — | ||
| Q2 24 | $89.8M | $149.0M | ||
| Q1 24 | $67.1M | — |
| Q4 25 | $262.8M | — | ||
| Q3 25 | $261.7M | — | ||
| Q2 25 | $284.7M | — | ||
| Q1 25 | $283.6M | — | ||
| Q4 24 | $285.0M | — | ||
| Q3 24 | $286.2M | — | ||
| Q2 24 | $282.1M | $148.6M | ||
| Q1 24 | $281.1M | — |
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.4B | $407.1M | ||
| Q1 24 | $1.4B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $230.0K | $28.9M |
| Free Cash FlowOCF − Capex | $-13.0K | $27.6M |
| FCF MarginFCF / Revenue | -0.1% | 290.5% |
| Capex IntensityCapex / Revenue | 2.6% | 13.2% |
| Cash ConversionOCF / Net Profit | 0.22× | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $230.0K | — | ||
| Q3 25 | $3.8M | — | ||
| Q2 25 | $3.0M | — | ||
| Q1 25 | $-4.3M | — | ||
| Q4 24 | $1.4M | — | ||
| Q3 24 | $6.1M | — | ||
| Q2 24 | $9.8M | $28.9M | ||
| Q1 24 | $-11.7M | — |
| Q4 25 | $-13.0K | — | ||
| Q3 25 | $3.7M | — | ||
| Q2 25 | $3.0M | — | ||
| Q1 25 | $-4.4M | — | ||
| Q4 24 | $1.3M | — | ||
| Q3 24 | $6.1M | — | ||
| Q2 24 | $9.7M | $27.6M | ||
| Q1 24 | $-11.7M | — |
| Q4 25 | -0.1% | — | ||
| Q3 25 | 41.1% | — | ||
| Q2 25 | 37.0% | — | ||
| Q1 25 | -52.4% | — | ||
| Q4 24 | 14.7% | — | ||
| Q3 24 | 69.6% | — | ||
| Q2 24 | 118.9% | 290.5% | ||
| Q1 24 | -149.7% | — |
| Q4 25 | 2.6% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.5% | 13.2% | ||
| Q1 24 | 0.7% | — |
| Q4 25 | 0.22× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.06× | — | ||
| Q3 24 | 11.85× | — | ||
| Q2 24 | 38.21× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
